10 percent weight loss means losing 10 pounds for every 100 you start with: 20 pounds from 200, 25 from 250. Studies have tracked what tends to shift around that point: blood sugar, blood pressure, breathing during sleep, the load on the knees, fat in the liver. Each number comes from a different study of different people, and none is a forecast for one person.
What 10 percent weight loss means in pounds
Multiply the starting weight by 0.10. It's a share, so the pounds change with the starting point.
| Starting weight | 10% of that weight | Weight after that loss |
|---|---|---|
| 160 lb | 16 lb | 144 lb |
| 200 lb | 20 lb | 180 lb |
| 250 lb | 25 lb | 225 lb |
| 300 lb | 30 lb | 270 lb |
BMI (a screening number based on weight and height) falls by the same 10 percent, so a BMI of 35 becomes 31.5. These are calculations, not goals. The neighboring landmarks have their own pages: what studies measured at 5 percent, at 15 percent and at 20 percent.
How many people in the big trials reached 10 percent
In the major GLP-1 trials, most people on the medicine crossed the line and most on placebo (a look-alike injection with no drug) did not.
| Trial and group | Reached at least 10% | Placebo |
|---|---|---|
| STEP 1, semaglutide 2.4 mg, 68 weeks, no diabetes | 69.1% | 12.0% |
| SURMOUNT-1, tirzepatide 5 mg, 72 weeks, no diabetes | 68.5% | 18.8% |
| SURMOUNT-1, tirzepatide 15 mg, 72 weeks, no diabetes | 83.5% | 18.8% |
| STEP 2, semaglutide 2.4 mg, 68 weeks, type 2 diabetes | 44.5% | 10.2% |
The STEP 1 figures come from the 2021 paper in the New England Journal of Medicine. The SURMOUNT-1 figures are printed in the Zepbound prescribing information (revised August 2026) and the STEP 2 figures in the Wegovy prescribing information (revised June 2026).
So about 7 in 10 people on semaglutide got there in STEP 1, and fewer than half in STEP 2, where everyone had type 2 diabetes. The STEP 1 results and SURMOUNT-1 results pages cover each trial.
What losing 10 percent of body weight looked like in one trial
STEP 2's average landed almost exactly on the landmark. It enrolled adults with overweight or obesity and type 2 diabetes, and after 68 weeks the 404 people assigned to semaglutide 2.4 mg averaged a 9.6% loss, against 3.4% on placebo (Davies et al., The Lancet, 2021). From an average start near 220 pounds, that's about 21 pounds versus 7.5. The Wegovy label reports what else moved:
| Measure at 68 weeks | Semaglutide 2.4 mg | Placebo | In everyday terms |
|---|---|---|---|
| Waist circumference | −9.4 cm | −4.5 cm | About 3.7 inches versus 1.8 |
| Systolic blood pressure | −3.9 mm Hg | −0.5 mm Hg | About four points versus half a point on the top number |
| HbA1c, starting at 8.1% | −1.6 points | −0.4 points | Roughly 8.1% down toward 6.5% |
HbA1c is a blood test that reflects average blood sugar over two to three months. Semaglutide also lowers blood sugar directly, so that row isn't the weight loss alone. And every row is a group average: some people lost far more, some far less.
Benefits of losing 10 percent: blood pressure and blood sugar
Look AHEAD was a U.S. trial of 5,145 adults with type 2 diabetes and overweight or obesity; its lifestyle program aimed for a 10% loss. A 2011 analysis sorted everyone by how much they lost in the first year and compared each group with people whose weight stayed stable (Wing et al., Diabetes Care, 2011). For people who lost 10 to under 15 percent:
| Improvement counted at one year | Odds compared with stable weight |
|---|---|
| Systolic pressure down at least 5 mm Hg | 2.29 times |
| HbA1c down at least 0.5 points | 5.44 times |
| Triglycerides down at least 40 mg/dL | 3.99 times |
| HDL ("good") cholesterol up at least 5 mg/dL | 2.30 times |
An odds ratio compares the chances of an improvement between two groups; it isn't the share of people helped. Each was higher than in the group that lost 5 to 10 percent. LDL cholesterol didn't track with weight loss. Nobody was assigned a target, so this shows association, not cause.
Heart events are a harder question. The lifestyle program itself didn't significantly reduce them. A later post hoc analysis (a question asked after the fact) found that people who lost at least 10% in the first year had a 21% lower risk of cardiovascular death, heart attack, stroke or hospital admission for angina over a median of about 10 years than people whose weight stayed stable or rose (Look AHEAD Research Group, Lancet Diabetes & Endocrinology, 2016). That's an association, not proof the loss caused it.
Sleep apnea: breathing pauses per hour
Sleep apnea means breathing repeatedly stops or turns shallow during sleep, scored as AHI (apnea-hypopnea index, episodes per hour). In the Wisconsin Sleep Cohort, 690 employed adults had overnight sleep studies four years apart. Relative to stable weight, a 10% loss predicted a 26% lower AHI, and a 10% gain a 32% higher one (Peppard et al., JAMA, 2000).
As arithmetic, 26% off an AHI of 20 is about five fewer events an hour. But that came from following people over time, not a treatment trial; only a repeat sleep study shows what changed for one person. Zepbound's label lists moderate to severe obstructive sleep apnea in adults with obesity as one of its uses; tirzepatide for sleep apnea covers those trials.
Knees: less force with every step
A 2005 study measured walking forces in 142 older adults with knee osteoarthritis (wear-related joint damage) and summed it up this way: each pound lost means a "4-fold reduction in the load exerted on the knee per step" (Messier et al., Arthritis & Rheumatism, 2005). By that ratio, 20 pounds lost from a 200-pound start is roughly 80 pounds less force per step, an estimate from one group with arthritis, not anyone else's knee.
A later analysis of the IDEA trial grouped 240 similar adults by how much they lost over 18 months. Pain, function and knee force improved more as weight loss grew, and losing 10 to 19.9 percent brought "substantial clinical and mechanistic benefits compared with less weight loss" (Messier et al., Arthritis Care & Research, 2018).
Liver: fat, inflammation and scarring
In a 2015 study from Havana, 293 people with biopsy-confirmed NASH (fatty liver with inflammation, now usually called MASH) were encouraged to change diet and activity for 52 weeks, then had a second biopsy. Everyone who lost at least 10% had a lower disease-activity score, 90% saw the inflammation resolve, and 45% had less fibrosis, or scarring (Vilar-Gomez et al., Gastroenterology, 2015).
The catch: only 30% of the group lost even 5%, so the 10% group was small, and there was no comparison group. The medicine side is on the semaglutide for fatty liver page.
Fresh numbers on where the medicines land
As of September 22, 2026, the day this article was written, a large new comparison had appeared: a network meta-analysis (a method that compares many drugs across many trials at once) published in The BMJ on July 8, 2026. Across 262 randomized trials and 99,791 participants, the extra weight loss at one year over lifestyle changes alone was 9.8 percentage points with semaglutide injections, 10.9 with oral semaglutide and 14.9 with tirzepatide (Nong et al., BMJ, 2026).
Those are differences, not total losses, which is why they sit below the trial averages above. The same analysis found that no drug convincingly improved quality-of-life scores past a 10-point threshold for the smallest change that matters to patients; every average difference was under 5 points. The scale and how a person feels are separate measurements.
What a 10 percent number cannot tell you
Every study above measured groups. None turns 10 percent into a promise about one person's blood pressure, knees or liver, and the medicine trials studied branded products, not Promise's compounded formulations.
Through Promise, semaglutide and tirzepatide are dispensed as compounded medications, which is different from an FDA-approved product: the formulations offered here are not FDA-approved. A licensed provider may still prescribe a compounded formulation; that decision is between the patient and doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The useful conversation treats 10 percent as one number beside the measurements that matter for that person, not as a finish line.
